Clinical scenarios for the use of S100β as a marker of hepatic encephalopathy

Figure 1 Serum concentrations of S100β (ng/mL) among groups. (1) Healthy subjects [0.05 (0.04-0.07)]; (2) Cirrhosis without HE [0.11 (0.06-0.14)]; (3) Cirrhosis with covert HE [0.16 (0.13-0.23)]; (4) Cirrhosis with overt HE [0.18 (0.14-0.28)]. Group 1 vs group 2, P < 0.001; Group 2 vs group 3, P < 0.016; Group 3 vs 4, P = 0.508. Healthy subjects vs all groups [0.14 (0.098-0.198)], P < 0.001.

Figure 2 S100β and PHES correlations between patients with cirrhosis and covert HE and non-covert HE. r = -0.413, P = 0.019. HE: Hepatic encephalopathy; PHES: Psychometric hepatic encephalopathy score.